361 related articles for article (PubMed ID: 19156355)
1. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.
Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Poole L; Kadesjö B
Eur Child Adolesc Psychiatry; 2009 Apr; 18(4):240-9. PubMed ID: 19156355
[TBL] [Abstract][Full Text] [Related]
2. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
3. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.
Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Schacht A; Kadesjö B
Eur Child Adolesc Psychiatry; 2009 Dec; 18(12):725-35. PubMed ID: 19466476
[TBL] [Abstract][Full Text] [Related]
5. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
6. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C; Sorbara F; Perrin E
Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
9. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Adeyi B; Caballero B; Hodgkins P; Civil R; Coghill DR
CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD.
Kratochvil CJ; Vaughan BS; Stoner JA; Daughton JM; Lubberstedt BD; Murray DW; Chrisman AK; Faircloth MA; Itchon-Ramos NB; Kollins SH; Maayan LA; Greenhill LL; Kotler LA; Fried J; March JS
Pediatrics; 2011 Apr; 127(4):e862-8. PubMed ID: 21422081
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
19. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
